Effect of roxadustat on renal anemia in hemodialysis patients

Effect of roxadustat on renal anemia in hemodialysis patients - Effect of roxadustat on renal anemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039598

Enrollment

Registered

2020-02-25

Start date

2022-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease

Interventions

Roxadustat tablets are orally administered each time at the start of dialysis. The dose of roxadustat tablet is appropriately increased or decreased depending on the blood hemoglobin concentration.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Maintenance dialysis patients receiving darbepoetin more than 40 microgram per week for treatment of renal anemia

Exclusion criteria

Exclusion criteria: Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis

Design outcomes

Primary

Measure	Time frame
Hemoglobin concentration, serum iron, transferrin saturation, serum ferritin, hepcidin	—

Countries

Japan

Contacts

Public ContactMichio Kuwahara

Saitama Tsukinomori Clinic Division of Nephrology

kuwahara@k-naika-cl.jp0487921811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026